Inovio Pharmaceuticals Inc Share Price Nyse
Equities
US45773H1023
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-14 | Stephens Starts Inovio Pharmaceuticals With Overweight Rating, $20 Price Target | MT |
05-13 | Transcript : Inovio Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Sales 2024 * | 418K 32.9M | Sales 2025 * | 19.8M 1.56B | Capitalization | 331M 26.09B |
---|---|---|---|---|---|
Net income 2024 * | -120M -9.45B | Net income 2025 * | -100M -7.87B | EV / Sales 2024 * | 793 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 16.7 x |
P/E ratio 2024 * |
-2.79
x | P/E ratio 2025 * |
-3.98
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.53% |
Latest transcript on Inovio Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 24/03/19 |
Peter Kies
DFI | Director of Finance/CFO | 60 | 31/05/02 |
Chief Tech/Sci/R&D Officer | - | 31/01/07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Benito
CHM | Chairman | 79 | 30/11/03 |
Lota Zoth
BRD | Director/Board Member | 64 | 31/12/17 |
Jay Shepard
BRD | Director/Board Member | 65 | 14/01/20 |
1st Jan change | Capi. | |
---|---|---|
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |